Medication nonadherence in schizophrenia can have serious implications including
relapses and hospitalization. Long-acting injectable (LAI) antipsychotics require fewer …

Introduction: In this review, the authors discuss the role of long-acting injectable
antipsychotics (LAIs) for schizophrenia, focusing on the effectiveness and new perspectives …

Background Long-acting injectable (LAI) antipsychotics use is associated with improved
adherence which can reduce the rate of relapse, hospitalization, and associated costs in …

This retrospective study evaluated the benefit of following different long-acting injectable
(LAI) initiation strategies based on the timing of behavioral and clinical events among …

This study was designed to assess healthcare resource utilization (HCRU) and costs in
patients with newly diagnosed schizophrenia based on timing and context of long-acting …

Dopamine receptor blocking agents (DRBAs), also known as antipsychotics, are
medications widely used to treat a growing number of mental health diagnoses. However …

Case management is a model of personalized intervention in people with severe mental
illness. To explore the treatment adherence and effectiveness of patients with severe …

To assess the impact of the route of administration and doses of second-generation
antipsychotics (SGAs) on treatment adherence, hospital admissions, and suicidal behaviour …

Background Long-acting injectable (LAI) antipsychotics can reduce relapse, hospitalization,
and costs in patients with schizophrenia. However, real-world evidence assessing the …

Background: Long-acting injectable antipsychotics (LAIs) may potentially benefit patients
requiring psychiatric hospitalization during the early stages of schizophrenia. However, few …